HyperlipidemiaPhase 1/2SPPPNCT00724217
Standard Process 21 Day Purification Program Project
A Phase 1/2 study testing Standard Process 21 Day Purification Program (SPPP) in people with Hyperlipidemia, run by Logan College of Chiropractic at 1 site in United States.
Trial summary
To determine the effects of a commercially available dietary modification plus nutritional supplement regimen, the Standard Process 21 day Purification Program (SPPP), on serum lipids, C-reactive protein (CRP), homocysteine, body mass index (BMI), body weight, blood pressure, and heart rate variability (HRV) in normal… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Hyperlipidemia
- What is being tested?
- Standard Process 21 Day Purification Program (SPPP)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2008to Mar 2009
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The two experimental groups will be 1. normal weight participants (BMI < 26) and 2. overweight participants (BMI 26 or above).
- All participants will have total cholesterol levels over 180.
- Both male and female subjects between the ages of 18-65 will be included in the study.
Who cannot join
- Exclusion criteria are based on factors that could interfere with the effects of the SPPP on the outcome measures and/or the safety of the participants as follows:
- Individuals with diabetes, heart, kidney, thyroid disorders, neurological diseases, and chronic disease will be excluded from the study.
- Female subjects who are pregnant or breast feeding and those using blood lipid modifying medications and/or supplements drugs and/or hypertension will be excluded from study.
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Logan College of Chiropractic
Chesterfield, Missouri, 63017
About this study
Official title: The Effects of the Standard Process 21 Day Purification Program, on Serum Lipids, C-Reactive Protein, Homocystine, Blood Pressure, and Heart Rate Variability in Normal Weight and Overweight Participants Who Have Total Cholesterol Levels Over 180.
To determine the effects of a commercially available dietary modification plus nutritional supplement regimen, the Standard Process 21 day Purification Program (SPPP), on serum lipids, C-reactive protein (CRP), homocysteine, body mass index (BMI), body weight, blood pressure, and heart rate variability (HRV) in normal weight (BMI < 26) and overweight (BMI 26 or above) participants who have total cholesterol levels over 180.
Read the detailed description
Elevated low-density lipoprotein (LDL) cholesterol concentrations are a risk factor for cardiovascular diseases. (1) Cholesterol lowering drugs are the most frequently prescribed medications in the U.S. and are known to have muscle, kidney and liver side effects for some users. Recent reviews conclude that benefits outweigh risks reporting statin and other cholesterol-lowering drugs to be safe and effective for most users. (2, 3, 4, 5) The new blood cholesterol level guidelines may recommend that more people take cholesterol lowering medications. According to the American Heart Association (AHA), total cholesterol levels should be below 180 mg/dL, with levels from 200 mg/dL to 239 mg/dL considered borderline high. Total cholesterol of 240 mg/dL and above is considered high. (6) However, published studies on the effect of blood lipids suggested that the actual cholesterol level itself is not the most important risk factor. It is the ratio between the level of total cholesterol and HDL that played a major role in the cardiovascular risk. The ideal HDL/cholesterol ratio should be higher than 25%. The ideal triglyceride/cholesterol ratio should be below 2.0. It is estimated that over 50 million adults in the U.S. have lipid levels higher than the above recommendations. (6) For persons who prefer conservative care, dietary modification is considered a first approach to the treatment and control of high cholesterol. (1, 7, 8) Hypertension is another risk factor for cardiovascular diseases and has close links to high blood cholesterol. (8) Between 40 and 50 million Americans have hypertension, which is defined as systolic blood pressure of at least 140 mm Hg or diastolic blood pressure of at least 90 mm Hg. (8) Hypertension is strongly, continuously, and independently related to coronary artery disease (CAD), stroke, renal disease, and all-cause mortality. For every 7.5-mm Hg increase in diastolic blood pressure, CAD risk increases 29% and stroke risk increases 46%. These risks have been shown for women as well as for men. Even within the high-normal blood pressure range, higher measurements result in greater risk of cardiovascular diseases. (9-10) It has been reported that diet and nutritional supplements are effective in reducing elevated blood pressure and reducing the risk of heart attack and stroke. (11-15) Diet and supplements have also been shown to have effects in reducing blood cholesterol. (16, 17)
Traditional dietary control has focused on reducing intake of saturated fat and cholesterol. Recent studies have suggested that the traditional focus of lipid management may have been overly simplistic and that diets might be more effective if more attention was given on including certain foods or factors rather than just avoiding saturated fat and cholesterol. Gardner et al 2005 reported improved results with more plant-based foods, such as whole grains, vegetables, legumes, and fruits while simultaneously limiting saturated fat and cholesterol. (17) It has been reported that nutritional supplements and diet can reduce serum lipids and blood pressure. There are no reports on the effects of nutritional supplement on HRV despite the close link of the autonomic nervous system activity on regulation of blood pressure.
The Standard Process 21 day Purification Program consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements. A recent case series of 28 chiropractic patients showed that the use of the SPPP resulted in significantly lowered total cholesterol. (18).
This study will investigate the effects of the SPPP in participants with elevated total cholesterol. The program requires the subjects to eat a modified; mostly fruits and vegetables diet and take the SPPP nutritional supplements for three weeks
The outcome measures of this study are supported in the literature as risk factors for cardiovascular and other conditions, e.g., serum lipids, C - reactive protein, homocystine, blood pressure, high BMI and heart rate variability (HRV).
- Conditions
- Hyperlipidemia
- Being tested
- Standard Process 21 Day Purification Program (SPPP)
- Medical subject headings
- Hyperlipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard Process 21 Day Purification Program (SPPP)Other
The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
Standard Process 21 Day Purification Program (SPPP)Other
The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
| Study group | Role | What they receive |
|---|---|---|
| Normal weight | Experimental | BMI < 26 Receives: Other: Standard Process 21 Day Purification Program (SPPP) |
| Overweight | Experimental | BMI >= 26 Receives: Other: Standard Process 21 Day Purification Program (SPPP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum lipids
Measured: Before and 3 weeks after starting SPPP (dietary modification + whole food supplements)
Secondary outcomes (1)
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, homocysteine, C-reactive protein, blood pressure, heart rate variability, body mass index
Measured: Before and 3 weeks after starting SPPP (dietary modification + whole food supplements)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2008 (estimated)
- Study startJul 2008
- Primary completionMar 2009 (estimated)
- Study completionMar 2009 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HyperlipidemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Logan College of Chiropractic
- Sponsor type
- University, hospital or other
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00724217
- Sponsor's protocol ID
- RD0530080135
- Acronym
- SPPP
- Status last verified
- Jul 2008
- First submitted
- 25 Jul 2008
- Last updated
- 29 Jul 2008
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of the Standard Process 21 Day Purification Program, on Serum Lipids, C-Reactive Protein, Homocystine, Blood Pressure, and Heart Rate Variability in Normal Weight and Overweight Participants Who Have Total Cholesterol Levels Over 180.
- ClinicalTrials.gov ID
- NCT00724217
- Acronym / sponsor ID
- SPPP / RD0530080135
- Conditions
- Hyperlipidemia
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Logan College of ChiropracticUniversity, hospital or other
- Study start
- Jul 2008
- Primary completion
- Mar 2009 (estimated)
- Study completion
- Mar 2009 (estimated)
- First posted
- 29 Jul 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the effects of a commercially available dietary modification plus nutritional supplement regimen, the Standard Process 21 day Purification Program (SPPP), on serum lipids, C-reactive protein (CRP), homocysteine, body mass index (BMI), body weight, blood pressure, and heart rate variability (HRV) in normal weight (BMI < 26) and overweight (BMI 26 or above) participants who have total cholesterol levels over 180.
Detailed description
Elevated low-density lipoprotein (LDL) cholesterol concentrations are a risk factor for cardiovascular diseases. (1) Cholesterol lowering drugs are the most frequently prescribed medications in the U.S. and are known to have muscle, kidney and liver side effects for some users. Recent reviews conclude that benefits outweigh risks reporting statin and other cholesterol-lowering drugs to be safe and effective for most users. (2, 3, 4, 5) The new blood cholesterol level guidelines may recommend that more people take cholesterol lowering medications. According to the American Heart Association (AHA), total cholesterol levels should be below 180 mg/dL, with levels from 200 mg/dL to 239 mg/dL considered borderline high. Total cholesterol of 240 mg/dL and above is considered high. (6) However, published studies on the effect of blood lipids suggested that the actual cholesterol level itself is not the most important risk factor. It is the ratio between the level of total cholesterol and HDL that played a major role in the cardiovascular risk. The ideal HDL/cholesterol ratio should be higher than 25%. The ideal triglyceride/cholesterol ratio should be below 2.0. It is estimated that over 50 million adults in the U.S. have lipid levels higher than the above recommendations. (6) For persons who prefer conservative care, dietary modification is considered a first approach to the treatment and control of high cholesterol. (1, 7, 8) Hypertension is another risk factor for cardiovascular diseases and has close links to high blood cholesterol. (8) Between 40 and 50 million Americans have hypertension, which is defined as systolic blood pressure of at least 140 mm Hg or diastolic blood pressure of at least 90 mm Hg. (8) Hypertension is strongly, continuously, and independently related to coronary artery disease (CAD), stroke, renal disease, and all-cause mortality. For every 7.5-mm Hg increase in diastolic blood pressure, CAD risk increases 29% and stroke risk increases 46%. These risks have been shown for women as well as for men. Even within the high-normal blood pressure range, higher measurements result in greater risk of cardiovascular diseases. (9-10) It has been reported that diet and nutritional supplements are effective in reducing elevated blood pressure and reducing the risk of heart attack and stroke. (11-15) Diet and supplements have also been shown to have effects in reducing blood cholesterol. (16, 17)
Traditional dietary control has focused on reducing intake of saturated fat and cholesterol. Recent studies have suggested that the traditional focus of lipid management may have been overly simplistic and that diets might be more effective if more attention was given on including certain foods or factors rather than just avoiding saturated fat and cholesterol. Gardner et al 2005 reported improved results with more plant-based foods, such as whole grains, vegetables, legumes, and fruits while simultaneously limiting saturated fat and cholesterol. (17) It has been reported that nutritional supplements and diet can reduce serum lipids and blood pressure. There are no reports on the effects of nutritional supplement on HRV despite the close link of the autonomic nervous system activity on regulation of blood pressure.
The Standard Process 21 day Purification Program consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements. A recent case series of 28 chiropractic patients showed that the use of the SPPP resulted in significantly lowered total cholesterol. (18).
This study will investigate the effects of the SPPP in participants with elevated total cholesterol. The program requires the subjects to eat a modified; mostly fruits and vegetables diet and take the SPPP nutritional supplements for three weeks
The outcome measures of this study are supported in the literature as risk factors for cardiovascular and other conditions, e.g., serum lipids, C - reactive protein, homocystine, blood pressure, high BMI and heart rate variability (HRV).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Normal weight | Experimental | Other: Standard Process 21 Day Purification Program (SPPP)BMI < 26 |
| Overweight | Experimental | Other: Standard Process 21 Day Purification Program (SPPP)BMI >= 26 |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- The two experimental groups will be 1. normal weight participants (BMI < 26) and 2. overweight participants (BMI 26 or above).
- All participants will have total cholesterol levels over 180.
- Both male and female subjects between the ages of 18-65 will be included in the study.
Key exclusion criteria (3 listed)
- Exclusion criteria are based on factors that could interfere with the effects of the SPPP on the outcome measures and/or the safety of the participants as follows:
- Individuals with diabetes, heart, kidney, thyroid disorders, neurological diseases, and chronic disease will be excluded from the study.
- Female subjects who are pregnant or breast feeding and those using blood lipid modifying medications and/or supplements drugs and/or hypertension will be excluded from study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard Process 21 Day Purification Program (SPPP)The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements. | Other | Normal weight |
| Standard Process 21 Day Purification Program (SPPP)The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based | Other | Overweight |
Primary outcome
Serum lipids
Time frame: Before and 3 weeks after starting SPPP (dietary modification + whole food supplements)
1 secondary outcome
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, homocysteine, C-reactive protein, blood pressure, heart rate variability, body mass index
Time frame: Before and 3 weeks after starting SPPP (dietary modification + whole food supplements)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2008.
Related trials for Hyperlipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruitingPhase 2
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
Diabetes, Lipodystrophy
RecruitingObservational study
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
Hypercholesterolemia, Dyslipidemias
Active, not recruitingPhase 3
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Lipodystrophy, Diabetes
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Standard Process 21 Day Purification Program (SPPP) in people with Hyperlipidemia, run by Logan College of Chiropractic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Jul 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rodger Tepe, PhD (636-230-1925, rodger.tepe@logan.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum lipids (time frame: Before and 3 weeks after starting SPPP (dietary modification + whole food supplements)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2008.